The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.
The new approach shows "The Talk" has a sequel.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.
United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.
The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.
The FDA will vote for or against the breast cancer drug by April 13, 2015.
The drugmaker is poised to cut 14 pipeline projects loose.
A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.
The regulator and patients will chat for two days in October.
The company is calling the move a withdrawal, as opposed to a recall.
It's the second for this cancer drug in two weeks.
HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.
The American College of Physicians says most women do not need an annual pelvic exam. The American College of Obstetrics and Gynecologists disagrees.
An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.
A coalition of organizations, including pharmaceutical company Sprout, kicked off a campaign urging the FDA to pay as much attention to women's sexual dysfunction needs as it does to men's.
The post-Chapter 11 pharmaceutical company unveiled its new name Thursday.
Its "Beauty is Bone Deep" campaign looks at beauty from the inside.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
The regulator is allowing generic makers room on the OTC contraceptive shelf.
Pfizer's consumer website for Advil in South Korea offers a strange appeal to women who experience menstrual pain.
The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.
Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.
The drugmaker may be able to settle around 3,800 cases for $100 million.
The White House has until Friday to issue a response to a Supreme Court injunction that temporarily eased birth-control coverage requirements.
A Penn State researcher thinks it can help women with menstrual cramps.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.